Carolina is currently the CEO of STAb Tx, a cell immunotherapy company spun out of Hospital 12 de Octubre and the CNIO in Madrid. We are developing next-generation T cell immunotherapies based on a novel approach, with several projects advancing in both hematologic and solid tumors. Over the past few years, we have engaged with key stakeholders in the cell therapy space, both in Spain and internationally. This has positioned us well to contribute meaningful insights into the field of cell immunotherapy, particularly within oncology, which is our primary area of focus.

As of March 2025, I have been selected as a member of the Termeer Foundation’s Class of 2025 Fellows — a program designed to support CEOs of early-stage biotech companies through a values-driven, leadership-focused curriculum. The initiative connects us with experienced C-suite executives in the biotech industry and addresses key challenges, also in the space of advanced therapies